Volume 4.00 | Jan 7

Cancer Stem Cell News 4.00 January 7, 2015
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter
 
TOP STORY
A Laminin 511 Matrix Is Regulated by TAZ and Functions as the Ligand for the α6Bβ1 Integrin to Sustain Breast Cancer Stem Cells
Researchers report that breast cancer stem cells produce a laminin 511 matrix that promotes self-renewal and tumor initiation by engaging the α6Bβ1 integrin and activating the Hippo transducer TAZ. [Genes Dev] Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
Parthenolide Inhibits Cancer Stem-Like Side Population of Nasopharyngeal Carcinoma Cells via Suppression of the NF-κB/COX-2 Pathway
Cyclooxygenase-2 (COX-2) was found to regulate cancer stem-like side population cells of nasopharyngeal carcinoma cells and enhance cancer stem-like cells’ characteristics such as higher colony formation efficiency and overexpression of stemness-associated genes. [Theranostics] Full Article

Morusin Inhibits Glioblastoma Stem Cell Growth In Vitro and In Vivo through Stemness Attenuation, Adipocyte Transdifferentiation, and Apoptosis Induction
The authors researched the growth inhibition effect of morusin on human glioblastoma multiforme cancer stem cells growth in vitro and in vivo and explored the possible mechanism of its activity. [Mol Carcinog] Abstract

Divergent Roles of CXCR3 Isoforms in Promoting Cancer Stem-Like Cell Survival and Metastasis
Investigators employed primary invasive ductal carcinomas, a panel of breast cell lines, and a xenograft model of metastatic breast cancer to examine the role of CXCR3 isoforms in the behavior of breast cancer stem-like cells and the contribution of each isoform to metastasis. [Breast Cancer Res Treat] Abstract

GRP78/BiP/HSPA5/Dna K Is a Universal Therapeutic Target for Human Disease
OSU-03012/sildenafil treatment killed brain cancer stem cells and decreased the expression of: NPC1 and TIM1; LAMP1; and NTCP1, receptors for Ebola/Marburg/Hepatitis A, Lassa fever, and Hepatitis B viruses, respectively [J Cell Physiol] Abstract | Full Article | Press Release

Cancer Stem-Like Cells of Ovarian Clear Cell Carcinoma Are Enriched in the ALDH-High Population Associated with an Accelerated Scavenging System in Reactive Oxygen Species
Researchers investigated the relationship between a cancer stem-like cell marker, aldehyde dehydrogenase 1 (ALDH1), and clinical prognosis using ovarian clear cell carcinoma tissue samples. [Gynecol Oncol] Abstract

Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells
Scientists present CD133-LV, a lentiviral vector presenting a single chain antibody against CD133 on its envelope, as a vehicle for the selective transduction of CD133-expressing glioblastoma stem cells. [PLoS One] Full Article

Immunophenotypic Characterization of Human Glioblastoma Stem Cells: Correlation with Clinical Outcome
The authors evaluated the prognostic potential of ability to generate glioblastoma stem cells (GSCs) in their series of 15 glioblastoma patients. β-tubulin III, nestin, CD133, GFAP and SOX-2 marker expression, both in primary glioblastoma multiforme cultures and in respective GSCs, was evaluated by flow cytometric analysis.
[J Cell Biochem]
Abstract

Targeting CD133 in the Enhancement of Chemosensitivity in Oral Squamous Cell Carcinomas-Derived Side Population Cancer Stem Cells
Investigators determined the function of CD133 on chemosensitivity of oral squamous cell carcinoma-cancer stem cells (OSCC-CSCs) by silencing CD133. They observed that the expression profile of CD133 in OSCC-side population cells, which exerted properties of CSCs, was significantly up-regulated than that of major population cells of OSCCs. [Head Neck] Abstract

Cancer Stem Cell Marker in Circulating Tumor Cells: Expression of CD44 Variant Exon 9 Is Strongly Correlated to Treatment Refractoriness, Recurrence and Prognosis of Human Colorectal Cancer
The expression of the CD44 variant exon 9 was investigated in order to elucidate its significance for cancer stem cells in circulating human colorectal cancer cells. [Anticancer Res] Abstract

 
REVIEWS
Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Currently the major approaches to targeting liver cancer stem cells (LCSCs) are ablating the expression of LCSC markers, disruption of key LCSCs signaling pathways, micro-RNA or siRNA targeting, inducing differentiation of LCSCs and the disruption of chemoresistance of LCSCs. However, complex crosstalk amongst gene regulatory pathways in LCSCs provides a major barrier in implementing these approaches in a clinical setting. [Curr Gene Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
OncoMed Doses First Patient in Phase I Clinical Trial of Novel Anti-DLL4/VEGF Bispecific Antibody
OncoMed Pharmaceuticals, Inc. announced dosing of the first patient in its anti-DLL4/VEGF bispecific antibody (OMP-305B83) Phase Ia clinical trial. The anti-DLL4/VEGF bispecific antibody is designed to have both anti-cancer stem cell and anti-angiogenic activity. [OncoMed Pharmaceuticals, Inc.] Press Release

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics
Blend Therapeutics, Inc. announced that it has secured $21 million in new funding. The proceeds of the financing will enable Blend to fully exploit its proprietary Pentarin™ platform, which creates novel, miniaturized biologic drug conjugates encapsulated in nanoparticles, representing a new class of cancer therapeutics. [Blend Therapeutics, Inc.] Press Release

Novel Anti-Cancer Drug, ONC201, Focus of Alliance between Oncoceutics and MD Anderson
Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug. [The University of Texas MD Anderson Cancer Center] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Exploring DNA Repair Pathways as Targets for Cancer Therapy
February 12-15, 2015
Cancun, Mexico

NEW Gordon Research Conference: Stem Cells & Cancer
February 15-20, 2015
Ventura, United States

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

NEW Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Positions – Functional Genomics of Stem Cells and Cancer (UT Southwestern Medical Center)

NEW Postdoctoral Fellow – Cancer Stem Cell Biology (University of Edinburgh)

Postdoctoral Fellow – Cancer Stem Cell Biology (Genome Institute of Singapore)

Postdoctoral Position – Cancer and Developmental Biology (University of California, Irvine)

Postdoctoral Fellow – Stem Cells and Cancer (Tsinghua University)

Postdoctoral Position – Pluripotent Stem Cell Biology and Cancer Research (Memorial Sloan-Kettering Cancer Center)

Principal Investigator – Cancer Biochemist (Wake Forest Baptist Medical Center)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us